@article{cb854a0219484d7ea1c1a5586cf2467f,
title = "Epigenome-wide association studies in Alzheimer's disease; achievements and challenges",
abstract = "Alzheimer's disease (AD) represents a devastating progressive neurodegenerative disease with a complex pathophysiology, affecting millions of people worldwide. Recent epigenome-wide association studies suggest a key role for epigenetic mechanisms in its development and course. Despite the fact that current evidence on the role of epigenetic dysregulation in aging and AD is convincing, the pioneering field of neuroepigenetics is still facing many challenges that need to be addressed to fundamentally increase our understanding about the underlying mechanisms of this neurodegenerative disorder. This perspective paper describes the current state of play for epigenetic research into AD and discusses how new methodological advances in the field of epigenetics and related data science disciplines could further spur the development of novel therapeutic agents and biomarker assays.",
keywords = "Alzheimer's disease, DNA methylation, epigenetics, methylome-wide association studies, DNA METHYLATION MICROARRAY, CPG SITES, BRAIN, VALIDATION, ANK1, AGE",
author = "{van den Hove}, {Daniel L. A.} and Riemens, {Renzo J. M.} and Philippos Koulousakis and Ehsan Pishva",
note = "Funding Information: Funds have been provided by the Joint Program?Neurodegenerative Disease Research (JPND) for the EPI-AD consortium (http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/Factsheet_EPI-AD.pdf). The project is supported through the following funding organizations under the aegis of JPND; The Netherlands, The Netherlands Organization for Health Research and Development (ZonMw); United Kingdom, Medical Research Council; Germany, German Federal ministry of Education and Research (BMBF); Luxembourg, National Research Fund (FNR). This project has received funding from the European Union?s Horizon 2020 research and innovation program under Grant Agreement No. 643417. Funding Information: Funds have been provided by the Joint Program—Neurodegenerative Disease Research (JPND) for the EPI‐AD consortium ( http://www.neurodegenerationresearch.eu/wp‐content/uploads/2015/10/Factsheet_EPI‐AD.pdf ). The project is supported through the following funding organizations under the aegis of JPND; The Netherlands, The Netherlands Organization for Health Research and Development (ZonMw); United Kingdom, Medical Research Council; Germany, German Federal ministry of Education and Research (BMBF); Luxembourg, National Research Fund (FNR). This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation program under Grant Agreement No. 643417. Publisher Copyright: {\textcopyright} 2020 International Society of Neuropathology",
year = "2020",
month = sep,
doi = "10.1111/bpa.12880",
language = "English",
volume = "30",
pages = "978--983",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley",
number = "5",
}